Longeveron Raises $30M, Eyes Q3 2026 HLHS Trial Readout as Q4 Revenue Falls
Longeveron secured a $30 million private placement, with $15 million funded in initial closing led by Coastlands Capital and Janus Henderson, and remains on track for pivotal Phase 2b ELPIS II results in Q3 2026 toward an HLHS BLA. Analysts forecast Q4 EPS loss of $0.38 on $106,200 revenue, down from $603,000 a year earlier.
1. Business Update and Funding
Longeveron secured a $30 million private placement, with $15 million funded in the initial closing led by Coastlands Capital and Janus Henderson Investors. The company remains on track for topline results from its pivotal Phase 2b ELPIS II trial in Q3 2026 and intends to pursue partnerships for its HLHS, Alzheimer’s and pediatric dilated cardiomyopathy programs targeting markets of ~$1 billion, $5 billion and $1 billion respectively. The HLHS program’s Rare Pediatric Disease designation could generate a Pediatric Priority Review Voucher valued at $150–205 million.
2. Q4 Financial Preview
Q4 results are projected to show a $0.38 EPS loss on $106,200 revenue, down from $603,000 in the year-ago quarter. This steep decline highlights Longeveron’s reliance on upcoming clinical milestones to drive funding and investor confidence as R&D investments continue to pressure the income statement.